Veloso et al. [26] reported HER-2 membranous expression in 50% of oral tumors and 25% of skin tumors and HER-3 cytoplasmic expression in 18% of oral melanomas and 6% of cutaneous neoplasms. Here, ERBB3 is linked to skin neoplasm.